肌少症对住院老年2型糖尿病患者远期预后的影响:前瞻性队列研究

Impact of Sarcopenia on Long-term Outcomes in Elderly Inpatients with Type 2 Diabetes Mellitus: A Prospective Cohort Study

  • 摘要:
    目的 分析肌少症对老年2型糖尿病(type 2 diabetes mellitus,T2DM)患者远期预后的影响。
    方法 连续入选2017年1月至2021年1月于北京协和医院老年医学科住院治疗、年龄≥65岁的T2DM患者。肌少症的评估采用2014年亚洲肌少症工作组(Asian Working Group for Sarcopenia,AWGS)制定的肌少症诊断标准,同时评估患者的共存疾病情况、功能状态、营养状态及合并老年综合征的情况。采取门诊随诊和电话随访的方法进行随访,随访内容包括发生重度失能、再住院以及全因死亡情况。采用Cox回归分析合并肌少症对老年T2DM住院患者远期预后(重度失能、再住院以及全因死亡)的影响。
    结果 共入选符合纳入和排除标准的老年T2DM住院患者244例,其中男性110例(45.1%)、女性134例(54.9%);年龄65~93岁,中位年龄74岁;25.4%(62/244)的患者合并肌少症。在3~ 7年(中位随访时间5.6年)的随访期内,合并肌少症的老年T2DM患者发生重度失能、再住院及全因死亡的比例均显著高于非肌少症老年T2DM患者(P均<0.001)。校正性别、年龄、共存疾病程度后,Cox回归分析显示,合并肌少症是老年T2DM患者发生重度失能(HR=4.693,95% CI:1.253~17.579,P=0.022)、再住院(HR=1.755,95% CI:1.053~2.926,P=0.031)以及全因死亡(HR=2.255,95% CI:1.078~4.713,P=0.031)的独立危险因素;此外,年龄校正的Charlson共病指数亦是患者全因死亡的危险因素(HR=1.237,95% CI:1.046~1.464,P=0.013)。
    结论 老年T2DM住院患者合并肌少症的患病率高,合并肌少症显著增加老年T2DM患者的远期不良预后风险。临床医师应重视对老年T2DM患者合并肌少症的筛查与干预,以提高其生活质量,改善其远期预后。

     

    Abstract:
    Objective To investigate the collective influence of sarcopenia on the extended prognosis of hospitalized elderly individuals with type 2 diabetes mellitus(T2DM).
    Methods Patients with T2DM aged 65 years and older, who were admitted to the Geriatrics Department of Peking Union Medical College Hospital between January 2017 and January 2021, were consecutively enrolled in the study. The presence of sarcopenia was evaluated based on the diagnostic criteria established by the Asian Working Group for Sarcopenia(AWGS) in 2014. Additionally, assessments were made on the patients' comorbidities, functional status, nutritional status, and geriatric syndromes. Follow-up was conducted through outpatient visits and telephone calls to monitor outcomes such as severe disability, rehospitalization, and all-cause mortality. Cox regression analysis was performed to investigate the impact of concurrent sarcopenia on the long-term prognosis of hospitalized elderly individuals with T2DM.
    Results A total of 244 elderly inpatients with T2DM who met specific criteria were included in the study, comprising 110 males(45.1%) and 134 females(54.9%), with ages ranging from 65 to 93 years and a median age of 74 years. Sarcopenia was observed in 25.4%(62/244) of patients. Over a follow-up period of three to seven years(median 5.6 years), elderly T2DM patients with sarcopenia exhibited significantly higher rates of severe disability, rehospitalization, and all-cause death compared to those without sarcopenia(all P < 0.001). Cox regression analysis, adjusting for gender, age, and comorbidities, revealed that sarcopenia was a significant predictor of severe disability(HR=4.693, 95% CI: 1.253-17.579, P=0.022), rehospitalization(HR=1.755, 95% CI: 1.053-2.926, P=0.031), and all-cause death(HR=2.255, 95% CI: 1.078-4.713, P=0.031). Additionally, the age-adjusted Charlson comorbidity index emerged as an independent risk factor for all-cause death(HR=1.237, 95% CI: 1.046-1.464, P=0.013).
    Conclusions The prevalence of sarcopenia is notably high among hospitalized elderly patients with T2DM, greatly affecting their long-term prognosis. It is imperative for clinicians to prioritize screening and implement interventions for sarcopenia in elderly T2DM patients to improve their quality of life and overall prognosis.

     

/

返回文章
返回